heat-shock-response-neurodegeneration

Heat Shock Response in Neurodegeneration

Overview

The heat shock response (HSR) is a highly conserved cellular protective mechanism activated by proteotoxic stress, including misfolded proteins, oxidative damage, and metabolic disruption. The HSR is mediated by heat shock factors (HSFs) that induce the expression of heat shock proteins (HSPs), molecular chaperones that prevent protein aggregation, facilitate refolding, and promote protein homeostasis. In neurodegenerative diseases, the HSR is frequently overwhelmed, making it an attractive therapeutic target.

Heat Shock Factor Family

HSF1: The Master Regulator

HSF1 is the primary transcription factor governing the HSR:

• Activation: Trimerization and DNA binding in response to proteotoxic stress
• Targets: HSP70, HSP90, HSP40, small HSPs (HSPB family)
• Regulation: Negative feedback through HSP90-HSF1 complex dissociation
• Post-translational modifications: Phosphorylation, acetylation, sumoylation fine-tune activity

HSF2 and HSF4

• HSF2: Involved in development and synaptic function
• HSF4: Expressed in neuronal populations; protective role in some contexts

Heat Shock Proteins in Neurodegeneration

HSP70 Family

The HSP70 family is the central effector of the HSR:

• HSP70 (HSPA1A/HSP72): Inducible stress response protein, strongest neuroprotective effects
• HSP73 (HSPA8/HSC70): Constitutively expressed, involved in protein folding and trafficking
• BiP/GRP78 (HSPA5): ER-resident HSP70, central to unfolded protein response

...

Heat Shock Response in Neurodegeneration

Overview

The heat shock response (HSR) is a highly conserved cellular protective mechanism activated by proteotoxic stress, including misfolded proteins, oxidative damage, and metabolic disruption. The HSR is mediated by heat shock factors (HSFs) that induce the expression of heat shock proteins (HSPs), molecular chaperones that prevent protein aggregation, facilitate refolding, and promote protein homeostasis. In neurodegenerative diseases, the HSR is frequently overwhelmed, making it an attractive therapeutic target.

Heat Shock Factor Family

HSF1: The Master Regulator

HSF1 is the primary transcription factor governing the HSR:

• Activation: Trimerization and DNA binding in response to proteotoxic stress
• Targets: HSP70, HSP90, HSP40, small HSPs (HSPB family)
• Regulation: Negative feedback through HSP90-HSF1 complex dissociation
• Post-translational modifications: Phosphorylation, acetylation, sumoylation fine-tune activity

HSF2 and HSF4

• HSF2: Involved in development and synaptic function
• HSF4: Expressed in neuronal populations; protective role in some contexts

Heat Shock Proteins in Neurodegeneration

HSP70 Family

The HSP70 family is the central effector of the HSR:

• HSP70 (HSPA1A/HSP72): Inducible stress response protein, strongest neuroprotective effects
• HSP73 (HSPA8/HSC70): Constitutively expressed, involved in protein folding and trafficking
• BiP/GRP78 (HSPA5): ER-resident HSP70, central to unfolded protein response

Neurodegeneration relevance:

• HSP70 overexpression prevents alpha-synuclein aggregation in PD models
• HSP70 reduces tau phosphorylation and aggregation in AD models
• HSP70 mitigates SOD1 aggregation in ALS models
• HSP70 enhances autophagy of damaged proteins

HSP90 Family

HSP90 maintains client protein stability:

• HSP90α/β: Cytosolic HSP90 isoforms
• TRAP1: Mitochondrial HSP90
• GRP94 (HSP90B1): ER-resident HSP90

Neurodegeneration relevance:

• HSP90 stabilizes tau, promoting pathological phosphorylation
• HSP90 co-factors (p23, HSF90AB1) implicated in aggregation
• HSP90 inhibitors promote tau degradation via HSF1 activation

Small HSPs (HSPB Family)

| Protein | Function | Neurodegeneration Role |
|---------|----------|------------------------|
| αB-crystallin (HSPB5) | Protein aggregation prevention | Elevated in AD/PD brains; protective in models |
| Hsp27 (HSPB1) | Cytoskeletal protection | Prevents neurofilament aggregation |
| Hsp20 (HSPB6) | Smooth muscle relaxation | Neuroprotective in stroke |
| CRYAB (HSPB4) | Lens protein, stress protection | Mutations cause cataracts; link to neurodegeneration |

Molecular Mechanisms

Chaperone-Assisted Protein Folding

HSR-induced HSPs prevent protein misfolding through coordinated mechanisms:

Key steps:

HSR-induced HSPs prevent protein misfolding:

Substrate recognition: HSP40 co-chaperones deliver misfolded clients to HSP70

ATP-dependent folding: HSP70 cycles through ADP/ATP states to facilitate folding

Co-translational quality control: HSP70/HSP90 coordinate nascent chain folding

Regulated client release: nucleotide exchange factors (NEFs) release folded proteins

Suppression of Protein Aggregation

HSPs directly suppress pathogenic protein aggregation:

• Sequestration: HSP70 binds aggregation-prone intermediates
• Disaggregation: HSP104 (yeast) and HSP70/HSP40 systems disentangle aggregates
• Refolding: ATP-dependent chaperone systems resolve misfolded proteins
• Targeting to degradation: Client proteins transferred to proteasome or autophagy

HSF1 Transcriptional Activation

Cross-Disease Relevance

Alzheimer's Disease

• Aβ toxicity: HSP70 reduces Aβ-induced neuronal death
• Tau pathology: HSP90 inhibition reduces tau levels via proteasomal degradation
• Synaptic protection: HSP70 preserves synaptic function in AD models
• Therapeutic approach: HSP90 inhibitors (17-AAG, Geldanamycin analogs)

Parkinson's Disease

• α-Synuclein aggregation: HSP70 prevents aggregation and toxicity
• LRRK2 mutations: HSP90 stabilizes mutant LRRK2; inhibitors promote degradation
• Mitochondrial stress: HSP60, HSP10 protect mitochondrial proteins
• Therapeutic approach: HSP70 inducers (geranylgeranylacetone, celastrol)

Amyotrophic Lateral Sclerosis

• SOD1 aggregation: HSP70, HSP110, HSP40 suppress mutant SOD1 aggregation
• TDP-43 pathology: HSP70 helps manage TDP-43 misfolding
• C9orf72 repeats: HSP70 family modulates repeat-associated toxicity
• Therapeutic approach: HSP70 overexpression; small molecule inducers

Huntington's Disease

• mHtt aggregation: HSP70, HSP40 suppress mutant huntingtin aggregation
• Transcription dysregulation: HSF1 activation restores transcription deficits
• Axonal transport: HSP90 maintains cytoskeletal integrity
• Therapeutic approach: HSP90 inhibitors reduce mHtt levels

Therapeutic Strategies

HSP90 Inhibitors

Mechanism: Inhibition releases HSF1 from HSP90 complex, activating HSR

| Drug | Stage | Notes |
|------|-------|-------|
| Geldanamycin | Preclinical | Natural product; hepatotoxic |
| 17-AAG (Tanespimycin) | Phase I/II | HSP90 inhibitor; tested in AD/ALS |
| 17-DMAG (Alvespimycin) | Phase I | Improved solubility |
| PU-H71 | Preclinical | Selective for tumor HSP90; CNS penetration? |
| PU-DZ8 | Preclinical | Better CNS penetration |

Clinical trials:

• NCT03748703: HSP90 inhibitor in ALS (completed)
• NCT04044547: HSP90 inhibitor in AD (ongoing)

HSP70 Inducers

Mechanism: Direct HSF1 activation increases HSP70 expression

| Compound | Mechanism | Evidence |
|----------|-----------|----------|
| Geranylgeranylacetone (GGA) | HSF1 activator | Gastroprotective; neuroprotective in models |
| Celastrol | HSF1 activator | Anti-inflammatory; neuroprotective |
| BGP-15 | HSP70 inducer | Niaspan analog; tested in PD |
| Arimoclomol | HSP70 co-inducer | Failed in ALS Phase III |

Clinical trials:

• NCT02258087: BGP-15 in Parkinson's disease (completed, mixed results)
• NCT00706147: Arimoclomol in ALS (Phase III, failed primary endpoint)

Gene Therapy Approaches

• AAV-HSP70: Viral delivery of HSP70 to brain regions
• AAV-HSF1: Constitutively active HSF1 for sustained HSR
• Cell therapy: MSC-based delivery of HSP70

Biomarker Connections

• CSF HSP70: Elevated in some AD/PD patients
• Blood HSP70: Correlates with disease severity in PD
• Peripheral blood mononuclear cells: HSP70 expression as treatment response marker

Clinical Trial Data

| Trial | Phase | Target | Outcome |
|-------|-------|--------|---------|
| HSP90i ALS | Phase I/II | SOD1/ALS | Safety, biomarkers |
| BGP-15 PD | Phase II | Neuroprotection | Mixed motor outcomes |
| Arimoclomol ALS | Phase III | FUS/SOD1 | Failed primary endpoint |

Future Directions

Blood-brain barrier penetration: Develop HSP90 inhibitors with improved CNS penetration

Selectivity: HSP90 isoform-selective inhibitors to reduce off-target effects

Combination therapy: HSP90 inhibition + immunotherapy for synergistic effects

Biomarker development: Validate HSP70/HSP90 as treatment response markers

HSF1 agonists: Direct HSF1 activators as safer alternatives to HSP90 inhibitors

See Also

• [Integrated Stress Response in Neurodegeneration](/mechanisms/integrated-stress-response)
• [Nrf2 Oxidative Stress Response](/mechanisms/nrf2-oxidative-stress)
• [Proteostasis Network in Neurodegeneration](/mechanisms/proteostasis-network)
• [HSP70 Protein](/proteins/hsp70-protein)
• [HSP90 Protein](/proteins/hsp90-protein)

bfe67bb53c3c532ef4237fa3323691ae27404769